Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Rated “Hold” by Wall Street Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have received an average rating of “Hold” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $220.00.

A number of research analysts recently weighed in on JSPR shares. Wall Street Zen raised Jasper Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. William Blair initiated coverage on shares of Jasper Therapeutics in a research report on Wednesday, October 14th. They set an “outperform” rating on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating on shares of Jasper Therapeutics in a research report on Tuesday, August 18th. Finally, Piper Sandler initiated coverage on Jasper Therapeutics in a research note on Wednesday, August 12th. They set an “overweight” rating and a $60.00 price target on the stock.

Jasper Therapeutics Price Performance

NASDAQ:JSPR opened at $14.76 on Friday. The firm has a market cap of $16.38 million, a price-to-earnings ratio of -0.31 and a beta of 3.30. The firm’s fifty day moving average price is $17.08 and its 200 day moving average price is $24.49. Jasper Therapeutics has a 1-year low of $9.45 and a 1-year high of $72.60.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Friday, August 14th. The company reported ($3.00) EPS for the quarter, topping the consensus estimate of ($8.03) by $5.03. As a group, analysts expect that Jasper Therapeutics will post -28.98 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation. Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.